JW Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

JW Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-5,025	Closed	-$21K	–	47
2017 Q1	$21K	Hold	5,025	–	–	﹤0.01%	41
2016 Q4	$21K	Hold	5,025	–	–	0.01%	36
2016 Q3	$19K	Hold	5,025	–	–	0.01%	38
2016 Q2	$17K	Hold	5,025	–	–	0.01%	36
2016 Q1	$27K	Hold	5,025	–	–	0.02%	38
2015 Q4	$62K	Sell	5,025 -202	-4%	-$2.7K	0.02%	38
2015 Q3	$76K	Hold	5,227	–	–	0.03%	50
2015 Q2	$102K	Hold	5,227	–	–	0.03%	48
2015 Q1	$95K	Hold	5,227	–	–	0.04%	45
2014 Q4	$123K	Buy	+5,227	New	+$121K	0.09%	41

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return

JW Asset Management's CTIC Position: Q2 2017 in Review

JW Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2017, closing a stake of 5,025 shares — an estimated $21K sold.

JW Asset Management first reported a position in CTIC in Q4 2014 and held it in 10 quarters. The position peaked at $123K in Q4 2014. 40 funds tracked by Wall St. Rank hold CTIC as of Q2 2017.

JW Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2017 after selling out during the quarter.
JW Asset Management sold 5,025 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2017, an estimated $21K.
JW Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and held it in 10 quarters.
JW Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $123K in Q4 2014.
40 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2017.

Based on JW Asset Management's 13F filing for Q2 2017, filed 4 Aug 2017.